ArticleEndocrine2022
Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Autoimmune diabetes mellitus after COVID-19 vaccination in adult population: a systematic review of case reports.BMC endocrine disorders · 2023Pooled it
- Endocrine system after 2 years of COVID-19 vaccines: A narrative review of the literature.Frontiers in endocrinology · 2022Pooled it
- Article
- Review
- Unique Features and Collateral Immune Effects of mRNA-LNP COVID-19 Vaccines: Plausible Mechanisms of Adverse Events and Complications.Pharmaceutics · 2025Review
- pDNA Impurities in mRNA Vaccines.Microorganisms · 2025Article
- New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.Internal medicine (Tokyo, Japan) · 2025Article
- An overview of HLA variants in COVID-19 vaccine-induced autoimmunity.International journal of molecular epidemiology and genetics · 2025Review
- Hypophysitis after COVID-19 vaccination in a patient with Rathke's cleft cyst: A case report.Human vaccines & immunotherapeutics · 2024Article
- COVID-19 vaccines and blood glucose control: Friend or foe?Human vaccines & immunotherapeutics · 2024Review
- New Onset of Type 1 Diabetes Mellitus Post-COVID-19 Vaccine.Journal of medical cases · 2024Article
- ASIA Syndrome: State-of-the-Art and Future Perspectives.Vaccines · 2024Review
- COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.Vaccines · 2024Article
- Review
- Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature.Diabetology international · 2024Article
- Proliferative diabetic retinopathy as the initial presenting feature of type 1 diabetes.Endocrinology, diabetes & metabolism case reports · 2023Article
- Review
- Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.Diabetology international · 2023Article
- Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review.World journal of diabetes · 2023Article
- Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?Vaccines · 2023Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been reported to trigger immune side effects. Type 1 diabetes as a manifestation of autoimmune/inflammatory syndrome induced by adjuvants has been reported in a limited number of cases after vaccinations. A few type 1 diabetes cases after SARS-CoV-2 vaccination have been reported. This study aims to report type 1 diabetes cases associated with the mRNA-based SARS-CoV-2 vaccination.
methodsWe report four cases of type 1 diabetes mellitus after mRNA-based SARS-CoV-2 vaccine, BNT162b2 (Pfizer-BioNTech). In the medical history, one subject had autoimmune thyroid disease. All patients had autoantibodies against glutamate decarboxylase.
resultsIn the presented case series, type 1 diabetes developed a few weeks after BNT162b2 vaccination. After developing type 1 diabetes, the insulin dose requirements of all patients decreased rapidly, and the need for insulin therapy in three patients disappeared during follow-up. Acute deterioration of glucose regulation in a patient followed by BNT162b2 administration may be due to vaccine-induced autoimmune diabetes.
conclusionVaccination with BNT162b2 may trigger type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.